Study of how the body absorbs a new HIV medicine
Part of Immune system & allergy, Infections clinical trials.
This early-stage study tests a new HIV medication (VH4524184) to understand how your body absorbs and processes it. You'll take a single dose of the medication with a small amount of radioactive tracer, which helps researchers track where the drug goes in your body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Healthy adults aged 18–55 with a normal body weight (BMI 18–32)
- No regular medications (must stop 30 days before) or supplements (must stop 14 days before)
- Female: not pregnant, not planning pregnancy, or past menopause; male: willing to use condoms and not donate sperm during the study
- No tobacco, nicotine, alcohol, caffeine, or grapefruit for at least 48 hours before and during the study
- No history of drug allergies, serious allergies, drug addiction, hepatitis, or HIV
- Good overall health with no stomach/bowel conditions, psychiatric illness, or recent serious infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new injectable drug (VH4011499) for safety and how the body processes it. It's for healthy adults without HIV, and participants will get either the study drug or a placebo (an inactive shot).
This study tests a new long-acting medicine that may help prevent HIV. It is given as an injection, and the study checks how safe it is and how it works in healthy volunteers.
This is an early-stage safety study testing a new investigational drug (VH4770359) in healthy volunteers. Researchers want to understand how the body processes the drug and ensure it is safe and well-tolerated.
This trial tests a new oral HIV medication (VH4524184) in people who have never taken HIV treatment before. It looks at how well the drug controls the virus and how safe it is.
This is an observational study that follows people to better understand how HIV and other infections (like sexually transmitted infections) happen and change over time. It may help researchers improve prevention and care, but it is mainly for monitoring rather than testing a new treatment.
This trial compares how HIV “reservoirs,” inflammation, and the gut microbiome change when people switch from daily HIV pills to long-acting injectable treatment. It may help you and your team understand what to expect with the switch and how your body responds.
Hear when a new HIV Infections trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.